A straightforward and highly diastereoselective synthesis of -4-hydroxypiperidines is presented. This method allows access to C2 and C4 substituted piperidines, bearing a tetrasubstituted carbon stereocenter at C4. -Disubstituted homoallylic amines and ketoaldehydes as carbonyl partners have been rarely used in aza-Prins cyclizations, expanding the scope of this reaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d4ob01807a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis of 4-hydroxypiperidines containing a quaternary stereocenter by aza-Prins cyclization.
Org Biomol Chem
January 2025
Univ Rennes, CNRS, ISCR - UMR 6226, F-35000 Rennes, France.
A straightforward and highly diastereoselective synthesis of -4-hydroxypiperidines is presented. This method allows access to C2 and C4 substituted piperidines, bearing a tetrasubstituted carbon stereocenter at C4. -Disubstituted homoallylic amines and ketoaldehydes as carbonyl partners have been rarely used in aza-Prins cyclizations, expanding the scope of this reaction.
View Article and Find Full Text PDF4-Hydroxypiperidines and Their Flexible 3-(Amino)propyloxy Analogues as Non-Imidazole Histamine H₃ Receptor Antagonist: Further Structure⁻Activity Relationship Exploration and In Vitro and In Vivo Pharmacological Evaluation.
Int J Mol Sci
April 2018
Department of Synthesis and Technology of Drugs, Medical University of Lodz, Muszyńskiego Street 1, 90-145 Łódź, Poland.
Presynaptic histamine H₃ receptors (H₃R) act as auto- or heteroreceptors controlling, respectively, the release of histamine and of other neurotransmitters in the central nervous system (CNS). The extracellular levels of several neurotransmitters are enhanced by H₃R antagonists, and there is a great interest for potent, brain-penetrating H₃ receptor antagonists/inverse agonists to compensate for the neurotransmitter deficits present in various neurological disorders. We have shown that 1-[(benzylfuran-2-yl)methyl]piperidinyl-4-oxyl- and benzyl- derivatives of -propylpentan-1-amines exhibit high in vitro potencies toward the guinea pig H₃ receptor (jejunum), with pA₂ = 8.
View Article and Find Full Text PDFAccess to 2,6-Disubstituted 4-Oxopiperidines Using a 6-Endo-trig Cyclization: Stereoselective Synthesis of Spruce Alkaloid and (+)-241D.
J Org Chem
January 2018
WestCHEM, School of Chemistry, The Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, United Kingdom.
A synthetic route to cis-2-methyl-4-oxo-6-alkylpiperidines has been developed using a 6-endo-trig cyclization of (E)-enones. The base-mediated intramolecular cyclization was found to be general for both alkyl- and aryl-substituted enones, providing the corresponding 4-oxopiperidines in high yields (80-89%). Stereoselective reduction of the 2,6-cis-disubstituted 4-oxopiperidines then gave the 2,4,6-cis,cis-trisubstituted 4-hydroxypiperidines in high diastereoselectivity.
View Article and Find Full Text PDFRole of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship.
Curr Drug Metab
January 2011
University of Ljubljana, Faculty of Pharmacy, Department for Pharmaceutical Chemistry, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Cytochrome P450-mediated bioactivation of drugs to reactive metabolites has been reported to be the first step in many adverse drug reactions. Metabolic activation of cyclic tertiary amines often generates a number of oxidative products including N-dealkylation, ring hydroxylation, α-carbonyl formation, N-oxygenation, and ring opening metabolites that can be formed through iminium ion intermediates. Therapeutic pharmaceuticals and their metabolites containing a cyclic tertiary amine structure have the potential to form iminium intermediates that are reactive toward nucleophilic macromolecules.
View Article and Find Full Text PDFStructure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.
J Immunol
February 2003
Department of Immunology, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806, USA.
A useful strategy for identifying ligand binding domains of G protein-coupled receptors has been the exploitation of species differences in antagonist potencies. We have used this approach for the CCR1 chemokine receptor with a novel series of antagonists, the 4-hydroxypiperidines, which were discovered by high throughput screening of human CCR1 and subsequently optimized. The structure-activity relationships for a number of different 4-hydroxypiperidine antagonists for human and mouse CCR1 were examined by receptor binding and functional assays.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!